I get MDGL is already in decent financial shape. Still, in the face of a sharp move up and key binary events still to come, it's not unusual at all to see a biotech even in good financial shape to take advantage of a sharp rise in price in such a scenario.
I'm waiting until the new year to take profits in a name to delay my tax bill but MDGL is on my short list of names to consider early next year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.